4DMedical posts FY26 revenue growth as commercial deployment ramps up
4DMedical reports 21% FY26 revenue growth as CT:VQ gains commercial adoption, global regulatory approvals and major healthcare partnerships.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| DUI | Weekly NTA - 31 January 2025 | 04/02/25 | ||
| DUI | Net Tangible Asset Backing | 10/04/18 | ||
| DUI | Change of Director's Interest Notice | 20/03/18 | ||
| DUI | Appendix 3B | 14/03/18 | ||
| DUI | Half Yearly Report to Shareholders | 14/03/18 | ||
| DUI | Net Tangible Asset Backing | 08/03/18 | ||
| DUI | Dividend Reinvestment Plan - Price | 01/03/18 | ||
| DUI | Update - Dividend/Distribution - DUI | 01/03/18 | ||
| DUI Weekly NTA - 31 January 2025 | |||
| 04/02/25 | |||
| DUI Net Tangible Asset Backing | |||
| 10/04/18 | |||
| DUI Change of Director's Interest Notice | |||
| 20/03/18 | |||
| DUI Appendix 3B | |||
| 14/03/18 | |||
| DUI Half Yearly Report to Shareholders | |||
| 14/03/18 | |||
| DUI Net Tangible Asset Backing | |||
| 08/03/18 | |||
| DUI Dividend Reinvestment Plan - Price | |||
| 01/03/18 | |||
| DUI Update - Dividend/Distribution - DUI | |||
| 01/03/18 | |||